Request Demo

Last update 08 May 2026

Modafinil

Last update 08 May 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryModafinil, a minuscule molecular compound marketed as PROVIGIL, received its initial approval in 1992. This drug is principally utilized to enhance vigilance among adult patients who are plagued by excessive sleepiness, a symptom of narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). However, it is important to note that PROVIGIL is not intended to treat the underlying causes of these sleep disorders; rather, its function is to heighten the patient's aptitude to remain alert during daylight hours. As a central nervous system stimulant, Modafinil operates by augmenting the activity of particular chemicals located within the brain that are implicated in regulating the sleep-wake cycle.

Drug Type

Small molecule drug

Synonyms

2-((diphenylmethyl)sulfinyl)acetamide, Alertec, Attenace

+ [25]

Target

DAT

Action

antagonists

Mechanism

DAT antagonists(Dopamine transporter antagonists)

Therapeutic Areas

Nervous System DiseasesRespiratory DiseasesOther Diseases

Active Indication

Idiopathic HypersomniaDisorders of Excessive SomnolenceNarcolepsy+ [3]

Inactive Indication

Alzheimer DiseaseApathyAttention Deficit Disorder With Hyperactivity+ [10]

Originator Organization

Teva Pharmaceuticals Europe BV

Active Organization

Libbs Farmacêutica Ltda.

Teva Pharmaceutical Industries Ltd.Nuvo Pharmaceuticals (Ireland) DAC

+ [3]

Inactive Organization

Cephalon, Inc.

License Organization

Neuraxpharm

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 1998),

NarcolepsySleep Apnea, ObstructiveSleep Disorders, Circadian Rhythm+ [1]

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC15H15NO2S

InChIKeyYFGHCGITMMYXAQ-UHFFFAOYSA-N

CAS Registry68693-11-8

223

Clinical Trials associated with Modafinil

NCT07263022

/ Not yet recruitingPhase 3IIT

Cognitive Strategies in Early Psychosis 2

The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last five years. The investigators will study how two study agents change decision making in people with psychosis, by asking participants to complete some brain games on the computer before and after taking the study agents. The investigators hope to improve our understanding of psychosis to help people in the future. The main research questions are:
* Does a single dose of modafinil change how people with psychosis play the brain games?
* Does a single dose of d-serine change how people with psychosis play the brain games?
* Does a single dose of modafinil change brain activity?
* Does a single dose of d-serine change brain activity?
Participants will:
* Complete an interview and self-report questionnaires.
* Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test.
* Complete functional Magnetic Resonance Imaging (fMRI) scans. fMRI uses magnets to take pictures of the brain. There will be six scanning appointments in the study, with two scans each. Appointments will be about a month apart.
* Take a single dose of a study agent during each scanning appointment. The study agent will be taken after the first fMRI. There are three study agents in total: modafinil, d-serine, and a placebo. Each participant will take each study agent twice during the study.
* Play brain games on a computer that measure decision making, thinking, and problem solving skills

Start Date11 May 2026

Sponsor / Collaborator

University of Minnesota

[+1]

CTIS2026-525163-41-00

/ Not yet recruitingPhase 2/3

Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)

Start Date01 Apr 2026

Sponsor / Collaborator

Radboud Universitair Medisch Centrum

NCT07568574

/ Enrolling by invitationNot Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

Start Date12 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Modafinil

100 Translational Medicine associated with Modafinil

100 Patents (Medical) associated with Modafinil

2,242

Literatures (Medical) associated with Modafinil

01 Dec 2026·Journal of Clinical Sleep Medicine

Real-world effectiveness and tolerability of wake-promoting agents for residual sleepiness in treated obstructive sleep apnea

Article

Author: Morgenthaler, Timothy I ; Auger, R Robert ; Seo, Heather ; Roberts, Jessica M

Residual sleepiness despite effective positive airway pressure (PAP) therapy remains a persistent clinical problem in obstructive sleep apnea (OSA). This retrospective study evaluated real-world use, effectiveness, and tolerability of modafinil, armodafinil, and solriamfetol in 50 adults with OSA and residual sleepiness. Most patients received modafinil (80%) as their initial agent. Complete, partial, and poor responses occurred in 26%, 44%, and 30% of patients, respectively. Adverse events were reported in 38%-predominantly neurologic and psychiatric-and led to discontinuation in ten cases. Response did not correlate with apnea severity, body mass index, or PAP adherence, and no single agent demonstrated superior benefit. These findings contrast with the stronger efficacy and tolerability reported in randomized controlled trials, underscoring the need for individualized therapy and realistic counseling about benefits and side effects when prescribing wake-promoting agents in clinical practice.

01 May 2026·NEUROPHARMACOLOGY

Pharmacological modulation of wakefulness and extracellular hypothalamic histamine release in adult male mice using TAK-925, modafinil, pitolisant, MK-8133 and Lu AF11167

Article

Author: Kornum, Birgitte R ; Herrik, Kjartan F ; Hviid, Camille G ; Sørensen, Gunnar

Histamine is a key regulator of wake and arousal, however its role in pharmacological modulation of wake is largely unknown. Specifically, whether histamine is always activated during pharmacologically induced wake promotion or even necessary for wake remains unclear. This study therefore measured EEG/EMG and accelerometer activity to determine sleep/wake states and locomotor activity and determined extracellular hypothalamic histamine levels using microdialysis following treatment with five wake- and sleep-modulatory compounds. We investigated the effects of three presumed wake-promoting compounds TAK-925 (danavorexton), modafinil and pitolisant as well as two presumed sleep-inducing compounds MK-8133 and Lu AF11167 in adult male mice. TAK-925 and modafinil dose-dependently prolonged wakefulness, whereas pitolisant had no effect. In contrast, TAK-925 and pitolisant increased extracellular histamine levels in hypothalamus, whereas modafinil had no effect. MK-8133 and Lu AF11167 both reduced wakefulness and decreased extracellular hypothalamic histamine levels. In vehicle-treated male mice, histamine levels were correlated with wakefulness but in pharmacologically treated male mice, this correlation was decoupled. These data demonstrate that wake can be modulated without modulating histamine signaling and vice versa.

01 Apr 2026·PHARMACOTHERAPY

Effectiveness of Stimulant Treatment in Preventing Fractures and Head Injuries in Patients With Narcolepsy: A Self‐Controlled Case Series Study

Article

Author: Fukasawa, Toshiki ; Zheng, Yunlong ; Takeuchi, Masato ; Kawakami, Koji ; Masuda, Soichiro ; Anno, Takayuki

ABSTRACT:

Background:

Previous cohort studies have investigated whether stimulants reduce injury risk in narcolepsy, but they faced potential biases such as confounding by indication and immortal time bias. We conducted a self‐controlled case series study to address these biases and assess the effect of stimulant use on the risk of fracture and head injury in patients with narcolepsy.

Methods:

We used a Japanese health insurance claims database to identify patients with narcolepsy who were newly exposed to stimulants and who experienced fracture or head injury. We then applied multivariable conditional Poisson regression models to estimate adjusted incidence rate ratios (aIRRs) and their 95% confidence intervals (CIs) for outcomes, comparing the focal window with the referent window. Subgroup analyses assessed individual stimulants (methylphenidate, modafinil, and pemoline).

Results:

Among 1790 new stimulant users, 233 had fracture and 189 had head injury. Overall stimulant use was not associated with fracture (aIRR, 0.89; 95% CI, 0.57–1.39) or head injury (aIRR, 1.40; 95% CI, 0.87–2.25). In subgroup analyses, methylphenidate use was associated with a lower fracture risk (aIRR, 0.28; 95% CI, 0.08–0.94) but did not affect head injury (aIRR, 1.16; 95% CI, 0.34–3.92). We observed no association between modafinil or pemoline and either outcome.

Conclusion:

Our results indicate that overall stimulant use did not decrease the risk of fracture or head injury in patients with narcolepsy. However, methylphenidate may help prevent fractures. Clinicians should balance the safety and effectiveness of each stimulant with additional preventive strategies for injury.

News (Medical) associated with Modafinil

01 Apr 2026

·www.sciencedaily.com

Millions start work too early. This drug helps them stay awake

Millions of people start work before sunrise—but their brains aren’t ready for it. A new clinical trial has found that the wake-promoting drug solriamfetol can significantly boost alertness in early-morning shift workers struggling with shift work disorder. Participants who took the drug were able to stay awake and function better throughout full shifts, with improvements in productivity, safety, and daily performance.Far more people work very early morning shifts than overnight schedules, yet many struggle with severe fatigue linked to shift work disorder. This condition can interfere with concentration, job performance, and safety. A new clinical trial led by researchers at Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early morning shift workers stay more alert. The findings were published in NEJM Evidence. "Until now, no clinical trial had tested a treatment for shift work disorder in early-morning shift workers, even though this is the most common type of shift schedule," said senior author Charles A. Czeisler, PhD, MD, chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. "This study addresses a major gap by focusing on the workers who start their day when most people are still asleep." Why Early Shifts Disrupt the Body's Clock Roughly one in four workers operates outside the standard 9 to 5 schedule, including those who begin work very early in the morning. Many people with these schedules do not consider themselves shift workers and instead see their routine as simply starting the day earlier than usual. However, they may still face a high risk of shift work disorder, which involves disrupted sleep patterns and persistent daytime sleepiness. "People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep. That makes staying alert extraordinarily difficult, even when they are highly motivated," said first author Kirsi-Marja Zitting, PhD, an investigator with the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. "They are often dealing with a double burden -- excessive sleepiness during work hours and difficulty sleeping enough when they have the chance to rest." Health and Safety Risks of Shift Work Disorder Shift work disorder is linked to a range of serious concerns, including reduced mental sharpness, lower productivity, increased risk of car accidents, and more workplace injuries. Medications such as modafinil are sometimes used to promote wakefulness, but these drugs have mainly been studied in overnight workers and can interfere with sleep later in the day. Solriamfetol, the drug evaluated in this study, is already approved for treating excessive sleepiness in people with obstructive sleep apnea and narcolepsy. Researchers considered it a promising option because it can promote alertness for extended periods without significantly disrupting later sleep. Clinical Trial Shows Improved Alertness and Performance The study included 78 early morning shift workers diagnosed with shift work disorder. Participants were randomly assigned to take either solriamfetol or a placebo on workdays over a four-week period. Researchers assessed their ability to stay awake in a controlled, low-stimulation setting during hours that matched their typical work schedule. Participants also reported on their daily functioning and met regularly with clinicians. After four weeks, those who received solriamfetol showed clear improvements. They were less sleepy and could remain awake longer during simulated work hours. Both participants and their doctors noted better overall functioning, improved work performance, and greater ability to manage daily tasks. "The improvement we saw is clinically meaningful. These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life," Czeisler said. "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost. This study shows we can do better for them." More Research Needed on Long-Term Effects The researchers emphasized that early morning shift workers have not been widely studied, and the current trial lasted only four weeks and included otherwise healthy adults. More research will be needed to understand the long-term effects of the treatment. The team is now enrolling participants for a follow-up clinical trial to study solriamfetol in overnight shift workers, which could help support broader approval for treating shift work disorder. In addition to Zitting and Czeisler, Mass General Brigham authors include Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, and Jeanne F. Duffy. Additional authors include Eileen B. Leary. Funded by Jazz Pharmaceuticals, Axsome Therapeutics, and Brigham and Women's Hospital Center for Clinical Investigation; NCT04788953(2021-03-09)

Clinical ResultDrug Approval

26 Mar 2026

·www.prnewswire.com

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY

NUTLEY, N.J., March 26, 2026 /PRNewswire/ -- Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, dose escalation study in adult patients with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2). Three dose strengths of E2086 per NT1 or NT2 participants will be assessed compared with placebo using objective and patient-reported measures of wake promotion. Narcolepsy is a sleep disorder resulting from disorganization of the sleep/wakefulness cycle. In patients with NT1, excessive daytime sleepiness and cataplexy (acute episodes of loss of muscle tone) are reported in association with low levels of the neurotransmitter orexin. In patients with NT2, excessive daytime sleepiness occurs, but without reports of cataplexy. As a selective orexin-2 receptor agonist, E2086 is hypothesized to compensate for the loss of orexin in patients with narcolepsy. In nonclinical studies, E2086 was shown to increase wake time and decrease cataplexy-like episodes in narcolepsy model mice and to prolong wakefulness in wild-type mice.1 In a recently completed proof-of-mechanism study in patients with NT1, compared with placebo and an existing treatment (modafinil), E2086 provided statistically significant and clinically meaningful increases in wake time as assessed by the objective maintenance of wakefulness test and by the patient-reported Karolinska sleepiness scale.2 For information about this study, please contact Eisai Medical Information at or 1-888-274-2378 (Monday through Friday 8:30 AM – 5:00 PM EST, excluding holidays). About E2086 E2086 is Eisai's in-house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Individuals with a deficiency of orexin demonstrate excessive daytime sleepiness (EDS), as exemplified by patients with narcolepsy Type 1, demonstrate a loss of orexinergic neurons, and low cerebrospinal fluid (CSF) orexin levels. E2086 has the potential to improve patients' symptoms by enhancing orexin receptor activity. About Eisai Inc. Eisai Inc. is a human health care (hhc) company dedicated to improving the lives of people affected by cancer, Alzheimer's disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them. Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good. Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities. To learn more, please visit us at and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages. SOURCE Eisai Inc. 21% more press release views with Request a Demo

Phase 2

08 Sep 2025

·www.prnewswire.com

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. These data demonstrate that once-daily dosing of E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1 (NT1). Continue Reading Clinical Trial Design This randomized, double-blind, single-dose, multiple crossover, Phase Ib clinical trial was conducted in the United States and Canada to evaluate the efficacy, safety, and tolerability of E2086 in people meeting criteria for NT1, compared with placebo and an existing treatment (modafinil). There were a total of 21 patients in the clinical trial (21 patients received the study medication, 19 patients completed the trial). Participants received a single dose of one of five treatments (E2086 5 mg, 10 mg, 25 mg, placebo, or modafinil) shortly after waking, efficacy assessments were conducted for each treatment. Efficacy was assessed using the objective Maintenance of Wakefulness Test (MWT)*1 to evaluate excessive daytime sleepiness (EDS), and subjective sleepiness was measured using the Karolinska Sleepiness Scale (KSS)*2 at the end of each MWT session. Clinical Trial Results As evaluated by MWT, all doses of E2086 demonstrated statistically significant longer sleep latencies*3 – a measure of the ability to stay awake – compared with placebo (P<0.0001 for all doses) and modafinil (E2086 5 mg: P=0.0009; E2086 10 mg and 25 mg: P<0.0001) (See the figure below). For the KSS, all doses of E2086 showed statistically significant higher alertness compared with placebo (P<0.0001), while E2086 10 mg and 25 mg demonstrated statistically significantly higher alertness compared with modafinil (P<0.0001). These outcomes confirmed the Proof of Mechanism for E2086. Treatment-emergent adverse events (TEAEs), based on the 21 patients who received the study medication in the clinical trial, exhibited a dose-dependent trend. The four most frequently observed TEAEs with E2086 included increased urinary frequency (E2086 5 mg: 14.3%, 10 mg: 23.8%, 25 mg: 52.4%), nausea (14.3%, 19.0%, 47.6%), dizziness (4.8%, 23.8%, 38.1%), and urinary urgency (9.5%, 19.0%, 38.1%). No participants discontinued due to TEAEs, and most TEAEs were mild to moderate in severity. No serious TEAEs were reported. Katsutoshi Ido, Ph.D., Chief Scientific Officer at Eisai, commented: "At World Sleep 2025, we presented data supporting the potential of E2086 to improve daytime wakefulness in people diagnosed with narcolepsy type 1. Narcolepsy is a condition with high unmet medical needs, characterized not only by excessive daytime sleepiness but also by symptoms such as cataplexy, hypnagogic/hynopompic hallucinations, and sleep paralysis, all of which significantly impair the quality of life of those affected. The efficacy and safety findings from this trial warrant further investigation in the narcolepsy patient population." Orexin is a neurotransmitter that plays a central role in regulating sleep and wakefulness. Inhibiting orexinergic neurons is believed to promote a natural transition from wakefulness to sleep. Conversely, activating orexinergic neurons is believed to help maintain a more stable state of wakefulness. From the perspective of inhibiting orexinergic neuron activity, Eisai has developed the insomnia treatment DAYVIGO ® (generic name: lemborexant) an orexin receptor antagonist that is available in more than 25 countries worldwide. Furthermore, leveraging the orexin platform established through the development of DAYVIGO, Eisai has created E2086, an orexin receptor agonist that activates orexinergic neurons. In addition to DAYVIGO, Eisai aims to contribute to people living with sleep disorders through the development of E2086. *1 Maintenance of Wakefulness Test (MWT): An objective test that evaluates the ability to stay awake in a sleep-conducive environment. The test is conducted in a quiet examination room with the lights turned off, consisting of four 40-minute sessions carried out at two-hour intervals throughout the day, during which the time taken to fall asleep (sleep latency) is measured using electroencephalography. *2 Karolinska Sleepiness Scale (KSS): A simple subjective scale used to assess the current intensity of sleepiness on a 9-point scale, ranging from "1 - Very clearly awake" to "9 - Very sleepy, struggling against sleepiness". *3 Sleep latency: The amount of time it takes to fall asleep. MEDIA CONTACTS: Eisai Co., Ltd. Public Relations Department, TEL: +81-(0)3-3817-5120 Eisai Europe, Ltd. EMEA Communications Department + 44 (0) 797 487 9419 Eisai Inc. (U.S.) Libby Holman + 1-201-753-1945 [Notes to editors] 1. About E2086 E2086 is Eisai's in house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Individuals with a deficiency of orexin demonstrate excessive daytime sleepiness (EDS), as exemplified by patients with narcolepsy Type 1, demonstrate a loss of orexinergic neurons, and low cerebrospinal fluid (CSF) orexin levels. E2086 has the potential to improve patients' symptoms by enhancing orexin receptor activity. 2. About narcolepsy Narcolepsy is a chronic sleep disorder that is characterized by EDS. Narcolepsy is classified into two subtypes, type 1 (narcolepsy with cataplexy) and type 2 (narcolepsy without cataplexy). Due to problems with fatigue, cognition, and persistence of residual symptoms despite treatment, disease burden for narcolepsy is high.1 References 1. Maski. K, et.al. Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy. J. Clinical Sleep Medicine. 2017, 13 (3) p419-, SOURCE Eisai Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 1

100 Deals associated with Modafinil

External Link

KEGG	Wiki	ATC	Drug Bank
D01832	Modafinil	N06BA07	DB00745

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Idiopathic Hypersomnia	Japan	Alfresa Pharma Corp.	21 Feb 2020
Disorders of Excessive Somnolence	Canada	Teva Pharmaceutical Industries Ltd.	24 Mar 1999
Narcolepsy	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Apnea, Obstructive	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Disorders, Circadian Rhythm	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleepiness	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Cephalon, Inc.	01 Jul 2005
Apathy	Phase 3	United States	Cephalon, Inc.	01 Jul 2005
Cataplexy	Phase 3	United States	Cephalon, Inc.	01 Oct 2004
Cataplexy	Phase 3	Canada	Cephalon, Inc.	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	United States	Cephalon, Inc.	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	Canada	Cephalon, Inc.	01 Oct 2004
Attention Deficit Disorder With Hyperactivity	Phase 3	United States	Cephalon, Inc.	01 Sep 2003
Depressive Disorder	Phase 2	Germany	Cephalon, Inc.	01 May 2008
Sleep Deprivation	Phase 2	Germany	Cephalon, Inc.	01 May 2008
Fatigue	Phase 2	United States	Cephalon, Inc.	01 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03772314 (Pubmed \| CNS Drugs) Manual	Phase 2	Narcolepsy \| Idiopathic Hypersomnia	-	Modafinil	jafjefbjpn(aivqyzoxfm) = hhgtyguxzp gagvjygsxi (ufxsicfcyb, 2.7) Not Met View more	Negative	21 Sep 2024
				Amphetamine-Dextroamphetamine	jafjefbjpn(aivqyzoxfm) = yxeyoplzod gagvjygsxi (ufxsicfcyb, 4.7) Not Met View more
NCT03621761 (COMBO-MS, ACTRIMS2023)	Phase 4	Multiple Sclerosis	336	Telephone-based Cognitive Behavioral Therapy (CBT)	zzyypyefwo(yjbpsozfva) = yewlpmxmtf czohhfzbho (bseiopdenn, 11.9)	Positive	30 May 2023
				Modafinil	zzyypyefwo(yjbpsozfva) = syxtslawcl czohhfzbho (bseiopdenn, 15.9)
NCT03621761 (COMBO-MS, CTgov)	Phase 4	Fatigue \| Multiple Sclerosis	343	Telephone-based Cognitive Behavioral Therapy (Cognitive Behavioral Therapy)	xwbsflebzs(yxuckylgce) = noczevqsjg wozmmepgot (ppuoaewphh, 11.9) View more	-	27 Dec 2022
				Modafinil (Modafinil)	xwbsflebzs(yxuckylgce) = gexcktvcey wozmmepgot (ppuoaewphh, 15.9) View more
NCT03083132 (CTgov)	Phase 2	Mental Fatigue \| Parkinson Disease	21	modafinil 50mg (Early-start)	cnlzobtekv(xbqhngbwfe) = arpxxhiyuo bzrwtakpnv (bmvmooohok, 2.53) View more	-	27 Oct 2021
				Placebo oral capsule+modafinil 50mg (Delayed-start)	cnlzobtekv(xbqhngbwfe) = nilamxlkft bzrwtakpnv (bmvmooohok, 1.62) View more
NCT01381718 (CTgov)	Phase 2	Cognition \| Neurotoxicity Syndromes \| Cognitive Dysfunction ... View more	112	Modafinil (Arm I - Modafinil)	boykchjgri(fefxhesvlf) = meqjotspxd ufixzdhnji (rneyawolxs, 0.71) View more	-	13 Aug 2021
				placebo (Arm II - Placebo)	boykchjgri(fefxhesvlf) = bhsdgrucsz ufixzdhnji (rneyawolxs, 1.06) View more
NCT03185065 (TRIUMPHANT-MS, CTgov)	Phase 3	Fatigue \| Multiple Sclerosis	141	placebo (Placebo)	cfiptgcnxy(sfbrxvceud) = fxbrrbrefe jzhbhyscns (raolwwaaca, cujhnlgqzt - umyhanmstz) View more	-	19 Oct 2020
				Amantadine (Amantadine)	cfiptgcnxy(sfbrxvceud) = xvrunzskda jzhbhyscns (raolwwaaca, qrrcrrfjsc - yvdkqqlrcu) View more
NCT03424681 (CTgov)	Phase 2	Alcohol Use Disorder	12	Modafinil (Modafinil)	cvwicjpkaa(okohmiijhy) = whimifqhvi umhkiawivk (lnkwfcgyaj, 27) View more	-	26 May 2020
				Placebo (Placebo)	cvwicjpkaa(okohmiijhy) = njwuazkxky umhkiawivk (lnkwfcgyaj, 32) View more
NCT01913327 (APD, CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	4	Aripiprazole+Modafinil (Aripiprazole)	zndcqsbsdu(dwvlpvunaq) = zeqypqeqeh xjzbealccc (ntiyqxcsbp, otklawzyxb - wheixcjmvt) View more	-	20 Apr 2020
				risperidone+Modafinil (Risperidone)	zndcqsbsdu(dwvlpvunaq) = eoflunxnyf xjzbealccc (ntiyqxcsbp, vlvijtouwt - reuqwabweu) View more
WSC2019	Not Applicable	Sleep Apnea, Obstructive	1,714	Solriamfetol 150 mg	egvdsbizqt(ydylaqswgf) = uswtelmodf kdehtglbzs (sdyqybiaic, 3% - 64%)	Positive	20 Sep 2019
NCT02494102 (ModOSA, CTgov)	Phase 4	Sleep Apnea, Obstructive \| Anesthesia \| Emergence Delirium	105	Placebo (Placebo)	dwnxqijlvw(jghmmyzgxp) = fpotahcxuw ijdiwalzjb (uvduitvtli, ggxijkffam - dgolruhosl) View more	-	20 Jun 2019
				Modafinil (Intervention)	iewfwuqvfc(qiutdqftjj) = eioixjxbvx oegftoxojx (blhxujmqke, abfxknzfbh - andagtxrsn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Modafinil

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation